The role of postprandial hyperglycemia and hyperlipidemia in CVD risk Robert J. Heine Invited Commentary Pages: 1 - 2
The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease Kambiz KalantariniaMark D. Okusa OriginalPaper Pages: 8 - 16
Endothelial function and the prediction of CVD in diabetes Raffaelle Bugiardini OriginalPaper Pages: 17 - 21
Coronary heart disease in women: Why the disproportionate risk? Helen Colhoun OriginalPaper Pages: 22 - 28
Exercise, fitness, and cardiovascular disease risk in type 2 diabetes and the metabolic syndrome Glen E. Duncan OriginalPaper Pages: 29 - 35
The safety and efficacy of statin therapy: An expanding database Eugene J. Barrett Clinical Trials Report Pages: 42 - 42
The PROactive study: Pioglitazone in the secondary prevention of macrovascular events in patients with type 2 diabetes Richard E. Pratley Clinical Trials Report Pages: 45 - 46
Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes Susanne TrostRichard E. PratleyBurton E. Sobel OriginalPaper Pages: 47 - 54
Low-carbohydrate or low-fat diets for the metabolic syndrome? Michael L. DansingerErnst J. Schaefer OriginalPaper Pages: 55 - 63
Metabolic syndrome in the elderly Matthew BechtoldJohn PalmerJames Sowers OriginalPaper Pages: 64 - 71
Should all patients with metabolic syndrome be treated with statins? Nicola AbateManisha Chandalia OriginalPaper Pages: 72 - 76
Risk of T2DM and impaired fasting glucose among pcos subjects: Results of an 8-year follow-up Monique Y. BoudreauxEvelyn O. TalbottSelma F. Witchel OriginalPaper Pages: 77 - 83